Latest Breaking News On - Clin cancer res - Page 1 : comparemela.com

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact: Investor contact: .

United statesRegion flamandeEdmond chanJenni mildonCiltacabtagene autoleucelEuropean commission grants conditional approvalLegend biotech united states incJanssen biotech incDrug administrationAmerican society of clinical oncologyEuropean commissionJanssen cilag internationalChinese company legend biotech to develop investigationalAmerican cancer societyCommittee for orphan medicinal productsJanssen research development

Elderly experience impressive improvement in survival after stem cell transplant

Elderly experience impressive improvement in survival after stem cell transplant
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Bymatthew shinkleMindy valcarcelAli bazarbachiAmerican university of beirutClinical cancer researchClinical cancerClin cancer resAmerican universityPublished march

Shocking results reveal imaging can detect early response to immunotherapy for melanoma

Shocking results reveal imaging can detect early response to immunotherapy for melanoma
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesByjosh friedmanMindy valcarcelMichaeld farwellAmerican association for cancer researchClinical cancer researchClinical cancerClin cancer resPenn medicineAmerican associationCancer research

MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. , a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its lead asset THIO showed highly potent anticancer activity in.

United statesSergei gryaznovBiotechnology incExchange commissionVlad vitocScientific officer sergei gryaznovClin cancer resNon small cell lung cancer

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof Shun Lu to its Clinical Advisory Board

/PRNewswire/ Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today.

United statesOpdivo nivolumabRita laeufleTechnology progressTechnology awardPhanes therapeutics incBoard member of anticancer associationShanghai jiao tong universityAmerican clinical oncology societyTel aviv universityCommittee memberShanghai jiao tong university chest hospitalMd anderson cancer centerInternational affairs committeePrnewswire phanes therapeutics incTechnology award of china association